CA2300850A1 - Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate - Google Patents

Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate Download PDF

Info

Publication number
CA2300850A1
CA2300850A1 CA002300850A CA2300850A CA2300850A1 CA 2300850 A1 CA2300850 A1 CA 2300850A1 CA 002300850 A CA002300850 A CA 002300850A CA 2300850 A CA2300850 A CA 2300850A CA 2300850 A1 CA2300850 A1 CA 2300850A1
Authority
CA
Canada
Prior art keywords
dexamethasone
treatment
oil
composition
eyes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300850A
Other languages
English (en)
French (fr)
Inventor
Yossi Bornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMATEAM DEVELOPMENT Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300850A1 publication Critical patent/CA2300850A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002300850A 1997-08-28 1998-08-26 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate Abandoned CA2300850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL121647 1997-08-28
IL12164797A IL121647A (en) 1997-08-28 1997-08-28 Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
PCT/IL1998/000411 WO1999011270A1 (en) 1997-08-28 1998-08-26 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate

Publications (1)

Publication Number Publication Date
CA2300850A1 true CA2300850A1 (en) 1999-03-11

Family

ID=11070569

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300850A Abandoned CA2300850A1 (en) 1997-08-28 1998-08-26 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate

Country Status (7)

Country Link
EP (1) EP1009409A1 (zh)
JP (1) JP2001514228A (zh)
CN (1) CN1271288A (zh)
AU (1) AU8883998A (zh)
CA (1) CA2300850A1 (zh)
IL (1) IL121647A (zh)
WO (1) WO1999011270A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312635A (pt) * 2002-07-15 2005-04-19 Alcon Inc Composições de implante farmacêutico lipofìlico não polimérico para uso intraocular
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
EP1864667B1 (en) * 2006-06-01 2013-09-04 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
KR101541416B1 (ko) 2006-06-01 2015-08-03 산텐 에스에이에스 후안부 질환 치료를 위한 스테로이드 전구약물의 용도
ES2719226T3 (es) 2007-12-04 2019-07-09 Santen Sas Composiciones que comprenden profármacos de corticosteroides tales como palmitato de dexametasona para el tratamiento de trastornos oculares
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS62270521A (ja) * 1986-05-16 1987-11-24 Green Cross Corp:The フルルビプロフエン眼投与製剤
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
JPH05124965A (ja) * 1991-11-06 1993-05-21 L T T Kenkyusho:Kk 局所用鼻・気管支疾患治療剤

Also Published As

Publication number Publication date
AU8883998A (en) 1999-03-22
EP1009409A1 (en) 2000-06-21
IL121647A (en) 2001-07-24
IL121647A0 (en) 1998-02-08
WO1999011270A1 (en) 1999-03-11
CN1271288A (zh) 2000-10-25
JP2001514228A (ja) 2001-09-11

Similar Documents

Publication Publication Date Title
RU2048812C1 (ru) Способ лечения воспалительных заболеваний глаза и средство для лечения воспалительных заболеваний глаза
Smith et al. Connective tissue, glycosaminoglycans, and diseases the thyroid
EP0041772B1 (en) Fat emulsion containing a steroid
DE69819751T2 (de) VERWENDUNG VON LÖSLICHEM REZEPTOR FÜR FORTGESCHRITTENE GLYKOSILIERUNG-ENDPRODUKTE (sRAGE) ZUR UNTERDRÜCKUNG DER BESCHLEUNIGTER ATHERIOSKLEROSE
Mackenzie Pharmacologic actions of 4-aminoquinoline compounds
Forrester et al. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats
Ren et al. Progesterone attenuates persistent inflammatory hyperalgesia in female rats: involvement of spinal NMDA receptor mechanisms
JP2003523925A (ja) 乾燥性眼病の局所治療のためのテトラサイクリンを含む眼科用溶液
US20210353770A1 (en) Delivery of Urea to Cells of the Macula and Retina Using Liposome Constructs
Badr et al. A polymeric aqueous tacrolimus formulation for topical ocular delivery
CN114376961A (zh) 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
US8470997B2 (en) Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
CA2300850A1 (en) Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
Hayasaka et al. Ocular changes after intravitreal injection of methanol, formaldehyde, or formate in rabbits
WO1994004155A1 (en) Dehydroepiandrosterone therapy for the treatment of eye disorders
DE69021791T2 (de) Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
US20190247302A1 (en) Materials and methods for treating ophthalmic inflammation
MXPA00001942A (en) Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
KR20230019108A (ko) 안구건조증 치료용 마이크로에멀젼
Woodward et al. Platelet-activating factor causes goblet cell depletion in the conjunctiva
New et al. Intestinal delivery of calcitonin in pig
US6696453B2 (en) Use of NF-κB inhibitors to treat dry eye disorders
Levy et al. Effect of lovastatin on lipoprotein fluidity in patients with hypercholesterolaemia
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
US20140213605A1 (en) Methods for treating eye disorders using opioid receptor antagonists

Legal Events

Date Code Title Description
FZDE Discontinued